Results 1 to 10 of about 52,189 (266)
Tandem CAR T-cells targeting CD19 and NKG2DL can overcome CD19 antigen escape in B-ALL
Frontiers in ImmunologyIntroductionChimeric antigen receptor (CAR) T-cell therapies have achieved remarkable success in treating B-cell malignancies, including acute lymphoblastic leukemia (B-ALL).
Jennifer Bolsée +5 more
doaj +3 more sources
Anti-CD19 CAR T cells potently redirected to kill solid tumor cells.
PLoS ONE, 2021 Successful CAR T cell therapy for the treatment of solid tumors requires exemplary CAR T cell expansion, persistence and fitness, and the ability to target tumor antigens safely.
Christine Ambrose +10 more
doaj +1 more source
A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors [PDF]
Journal of Translational Medicine, 2013 Chimeric Antigen Receptors (CARs) consist of the antigen-recognition portion of a monoclonal antibody fused to an intracellular signaling domain capable of activating T-cells. CARs displayed on the surface of transduced cells perform non-MHC-restricted antigen recognition and activating intracellular signaling pathways for induction of target cytolysis,
De Oliveira, SN +5 more
openaire +6 more sources
Viral Delivery of CAR Targets to Solid Tumors Enables Effective Cell Therapy
Molecular Therapy: Oncolytics, 2020 Chimeric antigen receptor (CAR) T cell therapy has had limited efficacy for solid tumors, largely due to a lack of selectively and highly expressed surface antigens.
Amin Aalipour +8 more
doaj +1 more source
TriBAFF-CAR-T cells eliminate B-cell malignancies with BAFFR-expression and CD19 antigen loss
Cancer Cell International, 2021 Background To investigate the effect of TriBAFF-CAR-T cells on hematological tumor cells. Methods TriBAFF-CAR-T and CD19-CAR-T cells were co-cultured with BAFFR-bearing B-cell malignancies at different effector/target ratios to evaluate the anti-tumor ...
Guangchao Li +11 more
doaj +1 more source
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies [PDF]
Journal of Clinical Investigation, 2016 Potent CD19-directed immunotherapies, such as chimeric antigen receptor T cells (CART) and blinatumomab, have drastically changed the outcome of patients with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). However, CD19-negative relapses have emerged as a major problem that is observed in approximately 30% of treated patients ...
Marco Ruella +20 more
openaire +2 more sources
International Journal of Nanomedicine, 2023 CAR-T cell therapy is effective in the treatment of certain hematological malignancies, and the expansion and functional persistence of CAR-T cells in vivo are crucial to clinical efficacy. The aim of this study was to investigate the potential of extracellular vesicles (EVs) modified with the CAR antigen to promote the efficacy of CAR-T cells in vivo ...
Yuanyuan Zhang +10 more
openaire +4 more sources
Hematology, Transfusion and Cell Therapy, 2023 Introduction: The recent active use of immunotherapy based on CD19/CD3 bispecific T-cell engager (blinatumomab), brings significant problems on monitoring Minimal Residual Disease (MRD) based on Multiparameter Flow Cytometry (MFC), due to possible CD19 ...
RM Pontes +9 more
doaj +1 more source
Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. [PDF]
PLoS ONE, 2013 Clinical trials targeting CD19 on B-cell malignancies are underway with encouraging anti-tumor responses. Most infuse T cells genetically modified to express a chimeric antigen receptor (CAR) with specificity derived from the scFv region of a CD19 ...
Bipulendu Jena +6 more
doaj +1 more source
Cells, 2022 Given the importance of B lymphocytes in inflammation and immune defense against pathogens, mice transgenic for Cre under the control of Cd19 promoter (Cd19Cre/+ mice) have been widely used to specifically investigate the role of loxP-flanked genes in B ...
Ying Zhao +9 more
doaj +1 more source